Compounds of the general formula I are described wherein R1 is hydrogen. lower alkyl, lower alkoxy. hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R2 is hydrogen. lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or -NHCH2CHROH; R3 is hydrogen or halogen; N is 1 or 2 The compounds of formula I are NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers, which have the key function in modulating neuronal activity and plasticity. This property makes them key players in mediating processes underlying development of the CNS as well as learning and memory formation. The compounds and be used in medicaments to treat conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections, and chronic and acute pain.
Quinolin-4-yl derivatives II and their use in treating neurodegenerative disease